Minerva Neurosciences, Inc.
NERV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $12 | $13 | $15 | $32 |
| G&A Expenses | $10 | $10 | $11 | $13 |
| SG&A Expenses | $10 | $10 | $11 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $23 | $25 | $45 |
| Operating Income | -$22 | -$23 | -$25 | -$45 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $23 | -$7 | -$7 | -$6 |
| Pre-Tax Income | $1 | -$30 | -$32 | -$52 |
| Tax Expense | $0 | $0 | $0 | -$2 |
| Net Income | $1 | -$30 | -$32 | -$50 |
| % Margin | – | – | – | – |
| EPS | 0.19 | -4.61 | -6.01 | -9.35 |
| % Growth | 104.1% | 23.3% | 35.7% | – |
| EPS Diluted | 0.19 | -4.61 | -6.01 | -9.35 |
| Weighted Avg Shares Out | 8 | 7 | 5 | 5 |
| Weighted Avg Shares Out Dil | 8 | 7 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $5 | $8 | $7 | $6 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $6 | -$22 | -$25 | -$45 |
| % Margin | – | – | – | – |